Shares of Hemogenyx Pharmaceuticals PLC (LON:HEMO) fell 4.8% on Wednesday . The company traded as low as GBX 1.96 ($0.03) and last traded at GBX 2 ($0.03), 494,766 shares traded hands during trading. A decline of 94% from the average session volume of 8,010,000 shares. The stock had previously closed at GBX 2.10 ($0.03).
The firm has a market capitalization of $7.23 million and a price-to-earnings ratio of -5.00. The business has a 50-day moving average of GBX 2.09 and a two-hundred day moving average of GBX 2.53. The company has a quick ratio of 12.36, a current ratio of 12.36 and a debt-to-equity ratio of 415.66.
Hemogenyx Pharmaceuticals Company Profile (LON:HEMO)
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants.
Recommended Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.